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Abstract
Introduction: Short accessory pathway (AP) effective refractory period (ERP) is one of the 
risk  factors  in  Wolff-Parkinson-White  syndrome  (WPW).  The  purpose  of  study  was  to 
evaluate the reproducibility of APERP measurement during a same electrophysiological study 
(EPS).  
Methods: EPS consisted of 2 APERP measurements performed prospectively in 77 patients for 
a WPW in control state (CS) at a cycle length of 400 ms (n=76) and after isoproterenol (n=56).
Results: In CS, 18 patients (24 %) had the same APERP at both measurements; 41 (54.6 %) 
had differences from 10 to 40 ms, 17 (22.4 %) had differences > 40 ms. Among 45 patients 
with initial APERP > 240 ms, 7 had an APERP ≤ 240 ms at 2nd study. Among 31 patients 
with initial APERP ≤ 240 ms, 5 had an APERP > 240 ms at 2nd study. Pearson's product-
moment correlation was 0.75. After isoproterenol, 5 patients (9 %) had the same APERPs; 37 
(66 %) had differences from 10 to 40 ms and 14 had differences > 40 ms. Among 38 patients 
with initial APERP > 200 ms, 12 had an AP ERP ≤ 200 ms at 2nd study. Among 18 patients 
with initial APERP ≤ 200 ms, 10 had still APERP ≤ 200 ms at 2nd study. Pearson's product-
moment  correlation  was  0.54.                                  
Conclusions: There  are  important  variations  of  APERPs  during  EPS  mainly  after 
isoproterenol  infusion.  Therefore  the  values  of  APERPs should  be  interpreted  cautiously.
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Introduction
The prevalence of a typical Wolff-Parkinson-White (WPW) pattern is estimated to be 0.1% 
[1]. Sudden cardiac death might be the first clinical manifestation of the WPW syndrome in 
previously asymptomatic individuals [2]. A recent study [3] reports a sudden cardiac death risk 
of 0.02%/patient/year. But the risk of sudden death is increased in some clinical situations. So 
it  is important  to detect  high risk form for developing fatal  arrhythmic events,  in order to 
propose a curative treatment by radiofrequency ablation in a selected asymptomatic population 
[4]. The WPW syndrome is considered as representing a risk of life-threatening arrhythmic 
events when the following association is observed [5]: 1. Sustained atrial fibrillation is induced 
[6]; 2. The shortest RR interval between preexcited beats is less than or equal to 240 ms n the 
control state in adults [6] (or an anterograde effective refractory period of accessory pathway 
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(APERP) is less than or equal to 240 ms) [7, 8]  Or the shortest RR interval between preexcited 
beats is less than 200 ms or an AP ERP is less than 220 ms (or 200 ms depending on authors)  
after isoproterenol infusion [9,10]. 
Other factors are discussed such as the presence of multiple accessory pathways and the male 
gender. Therefore, the measurement of the AP ERP during an electrophysiological study is 
important. Actually AP ablation is largely indicated and a short APERP might be sufficient to 
indicate  AP  ablation.  The  aim  of  this  study  is  to  evaluate  the  reproducibility  of  the 
measurement  of AP ERP during the same electrophysiological  study.                     
Methods
Population
Seventy seven patients, 56 males (73 %) and 21 females (27 %) aged from 8 to 57 years (mean 
age 31 ± 12 years), with a ventricular preexcitation syndrome were consecutively included in 
this  study;  46 patients  were asymptomatic  (60 %),  20 patients  had palpitations  (27 %),  7 
patients  had  history  of  unexplained  syncope  (7  %),  2  had spontaneous  documented  atrial 
fibrillation (3 %). Only 2 patients (3 %) had a history of life-threatening arrhythmic events 
(ventricular fibrillation or atrial fibrillation with fast ventricular conduction).                
Accessory pathway was septal located in 51 patients (left 23, right 28). Three patients had an 
anteroseptal location (4 %); 19 patients had a left lateral accessory pathway location (25 %) 
and  4  a  right  lateral  location  (5  %).                                               
Methods
This was a prospective study performed between 2004 and 2010 after informed consent. An 
electrophysiological  study  was  performed  in  patients  not  sedated  and  after  cessation  of 
treatment. Patients were studied by transesophageal route and/or intracardiac route [11]. The 
classical protocol was as follows:
- Incremental atrial  pacing was performed until  the highest rate conducted 1/1 through the 
accessory  pathway and/or  the  AV node.                                              
-  Programmed  atrial  stimulation  in  control  state  at  basic  cycle  lengths  of  400  ms  was 
performed: one atrial extrastimulus was delivered after 7 paced atrial stimuli at a cycle length 
of 400 ms from 390 ms until the AP refractory pathway or the atrial effective refractory period 
with decrement of 10 msec. 
The disappearance of the pattern of preexcitation indicated when the APERP was reached. The 
longest A1A2 that fails to conduct at the atria was considered as the effective APERP. This 
protocol was reproduced again after several minutes to study the reproducibility of the measure 
of  anterograde  effective  refractory  period.                                          
The method was used to  induce supraventricular  tachycardia.  The protocol  was performed 
during 80 consecutive electrophysiological  studies.  Three patients  were excluded from this 
protocol because sustained atrial fibrillation was induced at first programmed atrial stimulation 
and flecainide injection was required to stop it. In one patient the AP did not conduct in control 
state and the measurement of APERP was made only after isoproterenol.                         
In the absence of induction of a tachycardia conducted through the accessory pathway at a rate 
higher than 250 bpm, isoproterenol (0.02 to 10 µg.min-1) was then infused to increase the sinus 
rate to at least 130 bpm and the pacing protocol was repeated. APERP was determined twice at 
a basic cycle length of 400 ms. Isoproterenol was infused in only 56 patients: 9 patients did not 
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require  isoproterenol  infusion because they had  an electrophysiological  malignant  form in 
control state with the induction of an atrial fibrillation and short cycle lengths conducted by 
AP. Two other patients remained in atrial fibrillation without signs of malignancy after second 
programmed  stimulation  in  control  state.  Poorly-tolerated  orthodromic  tachycardia  was 
induced in 5 symptomatic patients during the basal study and catheter ablation was indicated 
without  evaluation  after  isoproterenol.  In  6  children,  isoproterenol  infusion  was  poorly-
tolerated  and programmed atrial  stimulation  was  not  repeated.                          
Definitions
Conduction over the accessory atrioventricular connection was evaluated by the measurement 
of the maximal  heart  rate with a 1 to 1 conduction over the accessory connection and the 
shortest atrial tachycardia cycle length at which there was 1 to 1 conduction over the accessory 
connection. A short APERP was defined in the present study as less than or equal to 240 ms in  
control state (CS) and less than or equal to 200 ms after isoproterenol.                    
Statistical  analysis                                    
Results were presented as mean and standard deviation and compared with the paired Student t 
test.  A  value  of  p  <  0.05  was  considered  to  be  significant.  Correlations  were  performed 
between 2 determinations of AP ERP and agreement was expressed according to the Pearson's 
correlation coefficient. It was obtained by dividing the covariance of the two variables by the 
product  of  their  standard  deviations.                                    
Results
Reproducibility of APERP determination in control state at basic cycle lengths of 400 ms  
(Figure 1):
Figure  1:  Representation  with  box  plot  of  the  value's  variability  around  the  median.  PRE=  AP  effective 
refractory  period  (APERP);  isu:  isooproterenol                                      
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The mean fastest cardiac rate conducted by the accessory pathway was 214±55 bpm in control 
state  and the  ranges  were  100 and  300  bpm.  The  mean  sinus  cycle  length  did  no  differ  
significantly during both measurements (805±12 vs 819±11msec). The dispersion of the two 
measurements of APERP is represented on a graphic in Figure 2. The mean value of APERP 
at the first study was 264±52 ms. Mean value of the second measure was 265±50 ms (NS). 
However, there were important individual changes of APERP values between both studies.
Figure 2:  Representation of the dispersion of  the 2 different  measurements  of  accessory  pathway refractory 
periods  with  an  atrial  pacing  at  basic  cycle  lengths  of  400  ms                                
At the first determination, APERP was more than 240 ms (mean 299±37) in 45 patients (59 
%); mean value was the same in the second study (299±37 ms); APERP became less than or 
equal to 240 ms at second measurement in 7 patients (15.5 %) and remained more than 240 ms 
in 38 patients (84.5 %). At the first APERP determination, 31 patients (41 %) had an APERP 
less than or equal to 240 ms: 24 patients had an APERP less than or equal to 240 ms at both 
studies (77 %); 7 patients had an APERP more than 240 ms at second study (22.5 %). The 
mean absolute difference between the two trials was 25.7 ms (±25.2 ms). The variations are 
reported in Table 1.
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Table 1: Mean values of variations of APERP in control state (CS) or with isoproterenol
Twenty-eight measurements (37%) were shorter in the second trial  than in the first  with a 
mean difference of 34±24 ms. Thirty measurements (40 %) were shorter in the first trial than 
in  the  second,  with  a  mean  difference  of  34±  23  ms.  The  Pearson’s  product  –  moment 
correlation  was  0.75.                                            
Reproducibility  of  APERP  determination  after  infusion  of  isoproterenol  (Figure  1):
The mean fastest  cardiac  rate conducted by the accessory pathway was 265±18 bpm after 
isoproterenol  infusion.  The  mean  cycle  length  between  2  measurements  does  not  differ 
significantly (475±12 mesc vs 479±14 ms).  The dispersion of the two measurements  with 
isoproterenol infusion was represented on a graphic in Figure 3.
Figure 3:  Representation of the dispersion of  the 2 different  measurements  of  accessory  pathway refractory 
periods  after  isoproterenol  infusion                                           
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The  mean  value  of  the  first  measurement  was  223±40  ms.  Mean  value  of  the  second 
measurement  was  224±48  ms  (NS).  Individual  data  differed.  At  the  first  APERP 
determination, 18 APERPs (32%) were less than or equal to 200 ms; 10 measures (56%) were 
less than or equal to 200 ms and reproducible at 2 measurements; 8 APERPs were more than 
200 ms at the second determination (46%). The mean absolute difference between two trials 
was 34±25.4 ms. Among 38 patients with initial APERP more than 200 ms, 12 measures were 
less than or equal to 200 ms at the second determination (33%). The individual variations are 
reported  in  Table  1.                                                
For 30 patients (53.4 %) the APERP was shorter at the second measurement than at the first, 
with a mean difference of 30±18 ms. For 21 patients (37.5 %) the first measure of APERP was 
the  shortest  with  a  mean  difference  of  47.6  ±  28.4ms.  The  Pearson's  product  –  moment 
correlation  was  0.54.                                           
Reproducibility  according  to  the  route  (intracardiac  or  transoesophageal)  of  
electrophysiological  study:                                     
Fourteen patients underwent transesophageal study and later intracardiac study to perform the 
accessory pathway ablation. The initial mean values of APERP measured at esophageal study 
were  significantly  shorter  than  the  values  measured  at  intracardiac  study,  but  other 
measurements did not differ significantly. The mean variations were similar either in control 
state (31±29 ms and 30±27 ms) or after isoproterenol (26±16 and 24±15 ms) (Table 2).
Table 2: Data obtained in patients studied by esophageal route and then by intracardiac route
APERP1: AP effective refractory period at first measurement;  APERP2: APERP at second measurement CS:  
control state; iso: isoproterenol. Data are expressed as mean ± standard deviation and ranges 
Reproducibility  according  to  the  age:                                
The mean age of our population was 31±12 years. In the youngest population (30 years old or 
less), representing 36 patients, the Pearson correlation coefficient was 0.675 in control state and 
0.58 after isoproterenol infusion. In the oldest population (more than 30 years old), representing 
36  patients,  the  Pearson  correlation  coefficient  was  0.78  in  control  state  and  0.46  after 
isoproterenol  infusion. The subgroups according to the age of the patient  were too small to 
verify  possible  relationships  between  the  age  and  the  variability  of  APERP.
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Reproducibility according to the location of accessory pathway:                           
There were no significant differences of APERP according to the location of AP: AP was left-
sided in 19 patients and the variations were 27±25 ms in control state and 25±13.5 ms after 
isoproterenol. AP was septal in 54 patients and the variations were 24±25.5 ms in control state 
and 35±27 ms after isoproterenol. AP was right lateral side in only 4 patients and variations 
(42.5±22  ms  in  control  state  and  35±21  ms  after  isoproterenol)  can  not  be  interpreted.
Among the 2 patients who have presented life-threatening arrhythmic events and 2 other  
patients with syncope and malignant form of preexcitation syndrome at electrophysiological  
study; all had a maximal heart rate with a 1 to 1 conduction over the accessory pathway was 
more than 240 bpm in control  state  during induced  sustained atrial  fibrillation.  AF stopped 
spontaneously and the protocol was performed in these patients. Two patients had an APERP of 
250 and 260 ms at the first measurement and a short value (210 and 230 ms) at the second  
measurement.  Other  patients  had  a  short  value  (190  ms)  at  both  measurements.   
Discussion
We reported important  variations of APERPs during electrophysiological  study mainly after 
isoproterenol  infusion.  This  may mean that  ERP measurement  with  isoproterenol  cannot  be 
relied  upon  for  assessing  risk.  The  variations  could  be  partially  explained  by  the  various 
conditions of the autonomic nervous system. The vagal and sympathetic activities constantly 
interact, and modulate the electrophysiological behaviour of the heart under different conditions 
such as postural changes, effort, and psychological activation [12,13]. A case of emergence of 
bidirectional accessory pathway conduction in adulthood reported by Nabar A [14] highlights 
the possible emergence  of an AP in adult  life.                                            
Fenici and al [15] studied the reproducibility of transesophageal pacing in patients with Wolff-
Parkinson-White  syndrome  by  two  transesophageal  electrophysiological  studies  which  were 
performed approximately 3 months apart. The results of this study demonstrated that changes of 
autonomic modulation could induce significant variations in the electrophysiological parameters 
that  were  commonly  used  to  define  arrhythmogenic  risk  in  WPW  patients.  But  the 
intraindividual coefficient  variation was less than 10% in all  patients [16].  It  was clear  that 
APERP,  which is  dependent  on the autonomic tone,  could  vary during electrophysiological 
study, depending on the initial stress of the patient, the occurrence of a vagal reaction or the 
induction  of  a  tachycardia.                                          
As showed by Castellanos et al [16], if the accessory pathway has a short effective refractory 
period, very high ventricular rates can occur after the onset of atrial fibrillation. Under these 
circumstances,  atrial fibrillation can be a life-threatening arrhythmia. The incidence of atrial 
fibrillation in the Wolff-Parkinson-White syndrome is approximately 11.5% [17]. Wellens had 
compared  the length of  the  refractory  period of  the  accessory  pathway with  the  ventricular 
frequency during spontaneous or electrically induced atrial fibrillation [10] and reported a good 
correlation  between  the  2  values.                                            
The classical values of 240 ms in controls state and 200 ms after isoproterenol as cut-off for the 
evaluation of the arrhythmic risk should be discussed and the values of APERP's interpreted 
carefully in association with other data of electrophysiological study. Male gender, young age, 
sport, septal accessory pathway (AP), multiple accessory pathways, short AP refractory period, 
atrial  fibrillation  (AF)  were  reported  as  risk  factors  of  sudden  death  in  WPW  syndrome 
[6,18,19].  Pappone and al considered only the induction of a re-entrant  tachycardia  or atrial 
fibrillation as  a  risk  factor  of  arrhythmic events  in  asymptomatic  patients.  The same group 
reported recently 3 risk factors of events and sudden death, the inducibility of tachycardia, a 
short AP refractory period (less than 250 ms in adults, 240 ms in children) and the presence of  
multiple  pathways  [7,8].                                           
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Limitations  of  the  study                                            
Some of our studies were performed by transesophageal route. However 14 of these patients had 
later an intracardiac study and the variations of APERPs were similar. Nanthakumar et al [20] 
have compared transesophageal route and intracardiac rout at 24 hour interval. Despite adequate 
reproducibility, transesophageal atrial stimulation was shown to fail to predict the AP-ERP by 
intracrdiac  stimulation.  Differences  in  stimulus  latency  was  responsible,  in  part,  for  the 
disagreement.  
Three  patients  were  excluded  after  induction  of  atrial  fibrillation  at  the  first  measurement, 
requiring flecainide to stop it. We can not prove the role of autonomic nervous system because 
no changes in sinus cycle length were found in the present  study. We have not  studied the 
reproducibility of  the ventricular  rate during induced atrial  fibrillation,  because AF was not 
always  inducible  or  required  flecainide  to  stop  it.                                      
Only  3  patients  had  a  spontaneous  malignant  form.  More,  the  ages  of  our  population  are 
heterogeneous and a difference between younger and older patients can not be excluded. The 
data are only applicable to non sedated patients. Accessory pathways were mainly septal located 
probably because the majority of our patients were asymptomatic. Similar data were noted by 
our group [11] in a larger cohort of 645 patients with a preexcitation syndrome. At least, our 
statistical  analysis  can  be  debatable.                                      
Conclusion
In  conclusion  this  prospective  study  reports  important  variations  of  APERP’s  during 
electrophysiological  study  mainly  after  isoproterenol  infusion.  The  study  highlights  the 
limitation of measurement of ERP as a predictor of the future risk.  The APERP in patients with 
WPW  should  be  interpreted  with  carefulness  in  association  with  other  data  of 
electrophysiological study. We suggest repeating the measurement in patients complaining of 
palpitations or syncope to avoid missing short values of APERP.                               
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